KBC Group NV Boosts Position in Illumina, Inc. (NASDAQ:ILMN)

KBC Group NV raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 2.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,399 shares of the life sciences company’s stock after buying an additional 883 shares during the period. KBC Group NV’s holdings in Illumina were worth $5,799,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in ILMN. Versant Capital Management Inc boosted its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC raised its position in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares during the period. Private Trust Co. NA grew its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc bought a new stake in shares of Illumina in the third quarter valued at about $63,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on ILMN shares. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Leerink Partners increased their target price on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research report on Thursday, October 17th. Finally, Barclays raised their price objective on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Trading Up 1.0 %

Shares of NASDAQ:ILMN opened at $133.01 on Friday. The business has a 50-day moving average price of $139.05 and a 200-day moving average price of $135.05. The stock has a market cap of $21.10 billion, a price-to-earnings ratio of -13.35 and a beta of 1.11. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 EPS. Equities analysts predict that Illumina, Inc. will post 4.13 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.